Skip to main content
. 2017 Mar 30;15:66. doi: 10.1186/s12967-017-1174-z

Fig. 1.

Fig. 1

Treatment scheme of the SAKK 19/05 trial. Patients received BE until progression or unacceptable toxicity. Upon disease progression, patients received standard chemotherapy with cisplatin and gemcitabine